V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10438319 | 10069228 | 0 | 88 | null | 2020-08-07 | 2020-08-17 | EC | 02 | null | DOXORUBICIN + OLARATUMAB | 100823772 |
| 10438324 | 10069229 | 1.7 | 69.4 | Palliative (P) | 2020-10-22 | 2020-10-22 | R GCVP | 02 | N | SORAFENIB | 101721919 |
| 10438757 | 10069230 | 1.7 | 62.2 | null | 2019-06-21 | 2019-06-21 | R CODOX M | 02 | null | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 101119060 |
| 10439142 | 10069232 | 1.63 | 80 | null | 2019-06-09 | 2021-03-05 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 2 | null | EXEMESTANE + RIBOCICLIB | 100337421 |
| 10439306 | 10069233 | null | null | null | 2018-08-20 | 2018-09-27 | Ipilimumab | 02 | N | CAPECITABINE + MITOMYCIN | 101529428 |
| 10439350 | 10069234 | null | null | 03 | 2020-08-24 | 2020-08-24 | CISPLATIN + FLUOROURACIL | 99 | N | BOSUTINIB | 101300168 |
| 10439777 | 10069235 | 1.71 | 87.4 | 03 | 2021-10-10 | 2021-10-10 | Cisplatin + Pemetrexed | 2 | N | IRINOTECAN + MDG | 101179068 |
| 10440586 | 10069237 | 1.75 | 53.4 | null | 2020-09-16 | 2020-09-17 | Bexarotene | 02 | null | MITOMYCIN INTRAVESICULAR | 100119563 |
| 10440602 | 10069238 | 1.67 | 74 | Curative (C) | 2022-01-10 | 2022-01-24 | null | 02 | N | DASATINIB | 101184031 |
| 10440649 | 10069239 | 1.77 | 68.6 | null | null | 2020-05-05 | FLAG + Idarubicin | 02 | null | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100497212 |
| 10440928 | 10069240 | 1.49 | 0 | null | 2020-06-17 | 2020-07-17 | Bevacizumab 7.5mg/kg | Y | null | ANAGRELIDE | 101293525 |
| 10441650 | 10069243 | 1.66 | 72 | Palliative (P) | 2017-12-05 | 2018-11-18 | Capecitabine + Mitomycin | N | N | PEMBROLIZUMAB + PEMETREXED | 100413108 |
| 10441740 | 10069244 | 1.5 | 94 | Curative (C) | 2022-02-17 | 2022-02-21 | MUK 8 TRIAL | 02 | N | GEMCITABINE + TREOSULPHAN | 100490571 |
| 10442870 | 10069246 | 1.72 | 79 | Palliative (P) | 2017-05-19 | 2017-06-11 | VISMODEGIB | 02 | N | BEXAROTENE | 100932057 |
| 10443050 | 10069247 | 1.52 | 76.8 | null | 2018-12-13 | 2018-12-17 | Bortezomib + Panobinostat + Thalidomide | N | null | RIALTO TRIAL | 100517493 |
| 10443097 | 10069248 | 1.93 | 84.6 | Curative (C) | 2018-06-04 | 2018-06-16 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 99 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100035968 |
| 10443345 | 10069250 | 1.82 | 80.4 | Neo-adjuvant (N) | null | 2020-08-25 | Irinotecan | 02 | N | DOXORUBICIN + OLARATUMAB | 101810969 |
| 10443658 | 10069251 | 1.67 | 76.4 | null | 2019-01-20 | 2019-01-20 | Fludarabine IV | 99 | null | PAZOPANIB | 100368663 |
| 10443699 | 10069252 | null | null | null | 2019-04-07 | 2019-04-09 | Gemcitabine + Capecitabine | N | null | CYCLOPHOSPHAMIDE + RITUXIMAB | 100521879 |
| 10444165 | 10069255 | 1.69 | 67.6 | 03 | 2019-07-24 | 2019-07-25 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | N | IDELALISIB + RITUXIMAB | 100926689 |
| 10444770 | 10069256 | 1.66 | 75.2 | null | 2021-08-15 | 2021-08-15 | VISMODEGIB | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101371771 |
| 10445399 | 10069258 | 1.86 | 77.2 | Adjuvant (A) | 2017-12-01 | 2019-02-16 | null | 02 | N | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 100709390 |
| 10447365 | 10069262 | 1.65 | 88.8 | Adjuvant (A) | 2019-11-30 | 2019-12-31 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | NILOTINIB | 100578787 |
| 10448427 | 10069266 | 1.51 | 71.2 | Neo-adjuvant (N) | 2019-03-03 | 2019-03-11 | ISATUXIMAB + POMALIDOMIDE | 02 | N | LIPOSOMAL DOXORUBICIN | 100597119 |
| 10449361 | 10069268 | 1.53 | 78.8 | Palliative (P) | 2018-10-27 | 2020-04-24 | Ixazomib | 02 | N | PARTNER TRIAL | 101620296 |
| 10450664 | 10069271 | 1.5 | 56.1 | Disease modification (D) | 2020-03-04 | 2020-03-22 | Fulvestrant + Ribociclib | 02 | N | CISPLATIN + PEMETREXED | 100421788 |
| 10451466 | 10069272 | 1.56 | 105.2 | Palliative (P) | 2018-09-17 | 2019-10-17 | Erlotinib | null | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101657859 |
| 10451525 | 10069273 | 1.56 | null | Curative (C) | 2021-12-08 | 2022-04-21 | Bortezomib + Melphalan +/- Pred | 02 | N | CYTARABINE + VENETOCLAX | 101813115 |
| 10451574 | 10069274 | null | null | Palliative (P) | 2019-10-18 | 2019-11-08 | Oxaliplatin + Raltitrexed | 02 | N | IDELALISIB | 101833820 |
| 10451796 | 10069277 | 1.75 | 86.4 | null | 2020-01-08 | 2020-01-10 | STAMPEDE TRIAL | 02 | null | GEFITINIB | 100355081 |
| 10454575 | 10069281 | 1.68 | 103 | null | 2015-11-04 | 2017-10-20 | GEMCARBO | 02 | null | OFATUMUMAB | 101407185 |
| 10454721 | 10069282 | 1.57 | 49.4 | Palliative (P) | 2022-02-12 | 2022-02-13 | Fluorouracil+Mitomycin+RT (Bladder) | null | N | MITOMYCIN INTRAVESICULAR | 101295477 |
| 10455491 | 10069285 | 1.55 | null | Palliative (P) | 2018-10-17 | 2018-12-06 | null | 02 | null | RUCAPARIB | 100792335 |
| 10455582 | 10069286 | 1.94 | 59 | null | 2019-05-07 | 2021-09-28 | null | null | null | INTERFERON ALFA | 101346254 |
| 10455599 | 10069287 | 1.5 | 49.9 | null | 2020-03-17 | 2020-03-19 | null | 02 | null | STAMPEDE TRIAL | 101486861 |
| 10456315 | 10069288 | 1.83 | 106.2 | null | 2020-12-03 | 2020-12-03 | Pemetrexed | null | null | ISATUXIMAB + POMALIDOMIDE | 100751880 |
| 10457185 | 10069289 | 1.78 | 59.2 | null | 2018-11-05 | 2018-11-05 | null | 02 | null | TIVOZANIB | 101304930 |
| 10457867 | 10069291 | 0 | 70.7 | 03 | 2019-03-19 | 2020-06-17 | DA | 01 | N | PETREA TRIAL | 100435008 |
| 10458219 | 10069293 | 1.84 | 90 | Curative (C) | 2022-02-15 | 2022-02-15 | null | 02 | N | NINTEDANIB | 100775748 |
| 10459636 | 10069295 | 1.67 | 105.2 | null | 2022-03-16 | 2022-04-04 | OSIMERTINIB | N | null | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 101531292 |
| 10460339 | 10069300 | 0 | 77 | Palliative (P) | 2021-06-30 | 2021-07-16 | Trial Unspecified | 02 | N | OBINUTUZUMAB | 101834345 |
| 10461875 | 10069304 | 1.59 | 84.4 | null | 2016-08-02 | 2016-09-05 | null | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101721378 |
| 10463139 | 10069307 | 0 | 70.8 | null | 2017-03-11 | 2018-01-31 | ISATUXIMAB + POMALIDOMIDE | 02 | null | OXALIPLATIN + MDG | 100821151 |
| 10463388 | 10069309 | 1.52 | 61.6 | null | 2019-08-08 | 2019-09-07 | EVEROLIMUS | 02 | null | ERLOTINIB | 100668308 |
| 10463581 | 10069310 | 1.7 | 59.9 | null | 2018-08-16 | 2018-08-17 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101189011 |
| 10463603 | 10069311 | 1.56 | 102.3 | null | 2019-05-10 | 2019-05-12 | OSIMERTINIB | 02 | null | PEMBROLIZUMAB + PEMETREXED | 101362817 |
| 10463797 | 10069313 | null | 97 | Curative (C) | 2017-06-14 | 2017-06-19 | LENALIDOMIDE + RITUXIMAB | 02 | N | GEFITINIB | 100361329 |
| 10464201 | 10069314 | null | null | Disease modification (D) | 2020-04-22 | 2020-04-22 | ANAGRELIDE | 02 | N | SUNITINIB | 100004424 |
| 10464465 | 10069315 | 1.88 | 79 | Palliative (P) | 2015-07-27 | 2015-07-27 | null | 02 | N | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 100103226 |
| 10464960 | 10069316 | 1.89 | 46.7 | Disease modification (D) | 2021-12-24 | 2022-01-06 | Gemcitabine+Paclitaxel (Neo-tAnGo) | null | N | BORTEZOMIB + MELPHALAN | 101572022 |